Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2015, Article ID 214680, 5 pages
http://dx.doi.org/10.1155/2015/214680
Research Article

Impaired Fibrinolysis in Angiographically Documented Coronary Artery Disease

1Faculty of Pharmacy, Federal University of Minas Gerais, Avenida Antonio Carlos 6627, 31270-901 Belo Horizonte, MG, Brazil
2Department of Haematology, University Hospital Southampton, Southampton, UK
3Faculty of Health Sciences, University of Southampton, Southampton, UK

Received 13 October 2014; Revised 27 January 2015; Accepted 27 January 2015

Academic Editor: Owen McCarty

Copyright © 2015 Adriano Basques Fernandes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. K. Wu, N. Aleksic, C. M. Ballantyne, C. Ahn, H. Juneja, and E. Boerwinkle, “Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease,” Circulation, vol. 107, no. 13, pp. 1729–1732, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. B. N. Bouma and L. O. Mosnier, “Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the interface between coagulation and fibrinolysis,” Pathophysiology of Haemostasis and Thrombosis, vol. 33, no. 5-6, pp. 375–381, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Koenig, D. Rothenbacher, A. Hoffmeister, M. Griesshammer, and H. Brenner, “Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 10, pp. 1701–1705, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Thögersen, J.-H. Jansson, K. Boman et al., “High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor,” Circulation, vol. 98, no. 21, pp. 2241–2247, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Paola Cellai, E. Antonucci, A. Alessandrello Liotta et al., “TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit,” Thrombosis Research, vol. 118, no. 4, pp. 495–500, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Silveira, K. Schatteman, F. Goossens et al., “Plasma procarboxypeptidase U in men with symptomatic coronary artery disease,” Thrombosis and Haemostasis, vol. 84, no. 3, pp. 364–368, 2000. View at Google Scholar · View at Scopus
  7. V. Schroeder, T. Chatterjee, H. Mehta et al., “Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography,” Thrombosis and Haemostasis, vol. 88, no. 6, pp. 1020–1025, 2002. View at Google Scholar · View at Scopus
  8. A. Santamaría, A. Martínez-Rubio, M. Borrell, J. Mateo, R. Ortín, and J. Fontcuberta, “Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level,” Haematologica, vol. 89, no. 7, pp. 880–881, 2004. View at Google Scholar · View at Scopus
  9. I. Juhan-Vague, P. E. Morange, H. Aubert et al., “Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the North and South of Europe,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 867–873, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Cesarman-Maus and K. A. Hajjar, “Molecular mechanisms of fibrinolysis,” British Journal of Haematology, vol. 129, no. 3, pp. 307–321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. H. van Tilburg, F. R. Rosendaal, and R. M. Bertina, “Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis,” Blood, vol. 95, no. 9, pp. 2855–2859, 2000. View at Google Scholar · View at Scopus
  12. E. Ceresa, E. Brouwers, M. Peeters, C. Jern, P. J. Declerck, and A. Gils, “Development of ELISAs measuring the extent of TAFI activation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 2, pp. 423–428, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Skeppholm, N. H. Wallén, K. Malmqvist, A. Kallner, and J. P. Antovic, “Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome,” Thrombosis Research, vol. 121, no. 2, pp. 175–181, 2007. View at Publisher · View at Google Scholar · View at Scopus